HHS announced a temporary policy allowing compounding pharmacies to produce six peptides: BPC‑157, TB‑500, DSIP, PT‑141, Sermorelin, and IGF‑1 LR3. Oct 29
The policy provides a legal prescription pathway for these substances despite FDA concerns about safety and efficacy. Oct 29